Literature DB >> 6235610

Clinical implications of portal hemodynamics after small-diameter portacaval H graft.

I J Sarfeh, E B Rypins, M Fardi, R M Conroy, G R Mason, K P Lyons.   

Abstract

To assess the role of portal hemodynamics in the development of postshunt encephalopathy, we studied 19 patients after small-diameter portacaval H grafting (SD-PCHG). We used contrast studies as well as technetium-labeled macroaggregated albumin injected into the portal vein to assess direction of portal flow. We then quantitated the mesenteric fraction of flow perfusing the liver by injecting macroaggregated albumin into a peripheral mesenteric vein tributary. We found that none of seven patients with prograde flow by both scintigraphy and angiography developed postoperative encephalopathy, but the incidence was 58% in the remaining patients (p = 0.02). The fraction of mesenteric flow perfusing the liver after SD-PCHG was 12% +/- 4%, but this did not significantly correlate with encephalopathy rates. We conclude that after SD-PCHG, prograde portal flow minimizes encephalopathy rates. Although encephalopathy occurs in patients with predominantly reversed flow, a subgroup of patients with reversed flow remain without symptoms. The absolute fraction of mesenteric flow perfusing the liver has less influence on encephalopathy rates than has direction of portal flow. This study identifies a complex relationship between portal hemodynamics and encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6235610

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  2 in total

Review 1.  Narrow-diameter portacaval shunts for management of variceal bleeding.

Authors:  J C Collins; E B Rypins; I J Sarfeh
Journal:  World J Surg       Date:  1994 Mar-Apr       Impact factor: 3.352

2.  A systematic appraisal of portacaval H-graft diameters. Clinical and hemodynamic perspectives.

Authors:  I J Sarfeh; E B Rypins; G R Mason
Journal:  Ann Surg       Date:  1986-10       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.